Kirby McInerney LLP Urges Investors in DoubleVerify Holdings, Inc. (DV) to Inquire About Their Rights in Class Action Lawsuit
[ LEARN MORE ABOUT THE CLASS ACTION ]
On February 28, 2024, DoubleVerify issued lower revenue growth expectations for the first quarter of 2024 due to 'a slow start by brand advertisers and a slow ramp by recently signed new large customers.' On this news, the price of DoubleVerify shares declined by $8.25 per share, or approximately 21%, from $39.24 per share on February 28, 2024, to close at $30.89 on February 29, 2024.
On May 7, 2024, in connection with its first quarter 2024 earnings report, DoubleVerify surprised analysts by cutting its full-year 2024 revenue outlook due to customers that were pulling back on their ad spending. On this news, the price of DoubleVerify shares declined by $11.79 per share, or approximately 38%, from $30.57 per share on May 7, 2024, to close at $18.78 on May 8, 2024.
Then, on February 27, 2025, when DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending, DoubleVerify also disclosed that the shift of ad dollars from open exchanges to closed platforms was negatively impacting the Company. On this news, the price of DoubleVerify shares declined by $7.83, or approximately 36%, from $21.73 per share on February 27, 2025, to close at $13.90 on February 28, 2025.
Finally, on March 28, 2025, market research company Adalytics Research, LLC released a report claiming that DoubleVerify's web advertisement verification and fraud protection services are ineffective, and that DoubleVerify customers are regularly billed for ad impressions served to declared bots operating out of known data center server farms. On the same day, The Wall Street Journal reported that DoubleVerify regularly misses detection of nonhuman traffic in contradiction to the Company's claims that it helps brand avoid serving ads to nonhuman bot accounts.
If you purchased or otherwise acquired DoubleVerify securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Best Stock to Buy Right Now: Constellation Brands vs. Altria
Key Points Constellation is grappling with tariffs and weak demand. Altria is dealing with declining smoking rates. One of these blue chip giants has a brighter future. 10 stocks we like better than Constellation Brands › Constellation Brands (NYSE: STZ) and Altria (NYSE: MO) are both often considered stable blue chip stocks for income investors. Constellation is one of the world's largest producers of beers, wines, and spirits, while Altria is the largest tobacco company in America. Over the past three years, however, Constellation's stock stumbled nearly 30% as Altria's stock rallied more than 40%. Let's see why the tobacco maker outperformed the alcoholic drink maker by such a wide margin -- and if it will remain the better investment for the foreseeable future. Why did Constellation's stock stumble? Constellation generates most of its revenue from its beer business, which sells popular brands like Modelo, Corona, and Pacifico. A smaller percentage comes from its wine portfolio, which includes Kim Crawford, Robert Mondavi, and The Prisoner, and its spirits business, which sells Casa Noble Tequila, Svedka Vodka, and High West Whiskey. It generates nearly all of its revenue in the United States. Constellation faces three major challenges. First, its younger consumers are drinking less beer. To cope with that slowdown, Constellation is launching new types of alcoholic beverages (like hard seltzer) and alcohol-free drinks. Second, its sales of lower-end wines are declining. To offset that pressure, it divested its cheaper brands and focused on strengthening its premium brands. Lastly, the Trump administration's tariffs are driving up the costs of importing its best-selling Mexican beers. The company can offset some of that pressure by shipping more of its beers in glass bottles instead of aluminum cans (which are exposed to those higher tariffs), but an estimated 39% of its beer shipments from Mexico are still delivered in cans. It also faces production bottlenecks at its Mexican plants. Therefore, Constellation's top-line growth is being throttled by the divestments in its wine and spirits division and its softening beer sales. At the same time, the unpredictable tariffs, inflationary headwinds, and capacity constraints will continue to compress its margins. From 2024 to 2027, analysts expect Constellation's revenue to decline from $10.2 billion to $9.9 billion as it continues to right-size its business. Its earnings per share (EPS) is expected to grow at a compound annual growth rate (CAGR) of 7%. Its business certainly isn't collapsing, but its near-term headwinds and a lack of catalysts are making it an unappealing investment. The company's stock looks cheap at 14 times forward earnings, and it pays a decent forward yield of 2.5%, but its upside potential could remain limited. Why did Altria's stock soar? Altria generates most of its revenue from its flagship Marlboro cigarettes but also sells other cigarette brands, cigars, and smokeless products like e-cigarettes, snus, and nicotine pouches. It spun off its international business as Philip Morris International in 2008 and now generates nearly all of its revenue from the U.S. market. Altria's domestic concentration can be a double-edged sword. On one hand, it's well-protected from tariffs and foreign-exchange headwinds. On the other hand, adult smoking rates in the U.S. have steadily declined over the past six decades. The company counters that pressure by raising its cigarette prices to offset its declining shipments, cutting costs, and buying back a lot of shares to boost its EPS. It's also aggressively expanding its portfolio of smokeless products (especially e-cigarettes and nicotine pouches) through investments and acquisitions to curb its long-term dependence on cigarettes. In 2022, Altria's $12.8 billion investment in the e-cigarette maker Juul backfired as the Food and Drug Administration (FDA) banned all of its products. But after that big write down, it acquired Njoy, which sells FDA-approved e-cigarettes, for $2.8 billion in 2023. It expects that acquisition to start boosting EPS in 2026. From 2024 to 2027, analysts expect Altria's revenue (net of excise taxes) to dip from $20.4 billion to $20.2 billion as its core cigarette business continues to shrink. They expect its EPS to decline this year as it laps some big one-time tax benefits and the sale of its rights to Philip Morris International's Iqos heated tobacco products. But from 2025 to 2027, Altria's EPS is expected to have a steady CAGR of 5%. Its stock still looks cheap at 12 times forward earnings, and it pays a hefty forward yield of nearly 7%. Altria is a slow-growth stock, but it arguably doesn't face as many pressing issues as Constellation Brands. The better buy: Altria Constellation's business might stabilize over the next few years, but there aren't enough compelling reasons to buy its stock. Altria also faces some long-term challenges, but its business seems more stable, it pays a bigger dividend, and trades at a lower multiple. Those strengths all make Altria the better stock to buy right now. Should you invest $1,000 in Constellation Brands right now? Before you buy stock in Constellation Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Constellation Brands wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor 's total average return is1,049% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025
Globe and Mail
2 hours ago
- Globe and Mail
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Key Points Technology remains at the heart of most growth opportunities. Artificial intelligence and the data centers needed to house these platforms are also key growth drivers. A handful of stocks from the healthcare arena are also capitalizing on contemporary technological developments. 10 stocks we like better than Amazon › Are you looking for passive growth investments with staying power that you won't need to constantly monitor? That's a combination that doesn't often co-exist for any individual stock. There are some exceptions, however. Here's a rundown of 10 such growth stocks that would be at home in nearly any growth-minded investor's portfolio. Still worthy after all these years It's such a commonly suggested pick that it's almost become a cliché. Nevertheless, e-commerce and cloud computing giant Amazon (NASDAQ: AMZN) remains one of the market's most promising long-term growth prospects. Yes, plenty of other companies like Walmart and Shopify are finally figuring out how to keep Amazon in check. These other players aren't exactly dethroning Amazon, though. Market research outfit Digital Commerce 360 reports Amazon's leading share of North America's e-commerce market is holding strong at around 40%, while Synergy Research Group says Amazon Web Services' share of global cloud computing is a market-leading 29%. Amazon may not be adding market share on either front, but being the biggest name in both businesses helps it maintain its share of each. As long as the e-commerce and cloud computing markets keep growing -- and they're each expected to -- Amazon remains a serious growth engine. Plugged into the semiconductor industry's ongoing growth While Amazon is a household name, Lam Research (NASDAQ: LRCX) is anything but. Don't let its lack of notoriety fool you, though. It's an important player within the ever-growing semiconductor market. No, Lam doesn't make microchips. It makes the equipment used to manufacture microchips. Thin-film layering, plasma etching, wafer-cleaning, plus the software needed to operate these technologies are all in its wheelhouse, and more. Chipmakers Intel, Samsung, and Taiwan Semiconductor Manufacturing are some of its customers, for perspective. Yes, other companies also make semiconductor manufacturing tools. Making microchips is a complicated process with many different specialized steps, though. Few other players in the business are able to offer the specific solutions that Lam Research can, however, just as no other name in the business can provide ASML 's ultraviolet lithography technology, or offer Axcelis Technologies ' ion implanters. We need all these tools, including Lam's. And that need isn't going away anytime soon. It's only going to grow, in fact. An outlook from Precedence Research suggests the worldwide semiconductor market is set to double in size between now and 2034. Growth in a social and economic silo is still growth Amazon may be the powerhouse e-commerce name where you live, but that's not the case everywhere. In its home country of China, Alibaba (NYSE: BABA) is king, with collective control of about 40% of that online shopping market (according to numbers from wealth management firm DBS Treasures). It's doing pretty well with several of China's neighboring countries, too. All told, Alibaba's Tmall and Taobao e-commerce platforms did nearly $20 billion worth of business last year, up 29% year over year. And yet, this company's got far more ways to make money. It operates a logistics and delivery arm, a digital entertainment business, and perhaps most important, a cloud computing division that's also waist-deep into artificial intelligence. Remember the Qwen platform that posed a credible threat to ChatGPT, Google's Gemini, and then-buzzy DeepSeek earlier this year? Well, Qwen is Alibaba's developmental AI. As long as the Pacific Rim chooses to build its economy and technological landscape in a manner that's somewhat walled off from the Western world's, Alibaba stock is a growth investment that's parallel to -- rather than overlapping with -- Amazon. The growing norm in operating rooms Given how technology has become the centerpiece of most aspects of our lives, it should come as no surprise that it's also now frequently found within the healthcare industry. It's even found within operating rooms, in the tools used by surgeons. And one company dominates this sliver of the market: Intuitive Surgical (NASDAQ: ISRG). It makes the da Vinci surgical robot that's becoming the go-to solution for performing a growing number of surgical procedures ranging from hysterectomies to mitral vale repair to gastric sleeves to colostomies, just to name a few. Intuitive Surgical reports its da Vinci robots helped perform nearly 2.7 million procedures last year, up 17% from 2023's count. Here's the thing -- this still only scratches the surface of the tool's potential. Intuitive Surgical regularly adds capabilities to the da Vinci's toolkit at the same time more and more surgeons become qualified to use it, making them more likely to use this tech on one of the 300 million surgical procedures performed worldwide every year. Simultaneously, Intuitive Surgical is still developing new solutions like the Ion for lung biopsies and Hub, which records and shares surgical procedures. Analysts are calling for 25% top-line growth from Intuitive Surgical this year, to be followed by 15% and 17% revenue growth in 2026 and 2027, respectively. This is likely only a taste of what's to come further down the road, as this tech continues to prove itself. You've actually never heard of most software You're certainly familiar with Microsoft 's Windows operating system, and you may well be a regular user of its office productivity tools like Word and Excel. What you may not realize, however, is that most software is so industry-specific that you've likely never even heard of it. Case in point: Cadence Design Systems ' (NASDAQ: CDNS) Fidelity CFD (computational fluid dynamics) that digitally tests the behavior of fluids under certain conditions, or its Allegro X Design Platform, used to make printed circuit boards. Most people would never need such a specialized solution. But the few who need these tools desperately need them to do their job, and will pay a premium to gain access to them. This marketability is only part of the argument for buying and holding this stock for the long haul, however. Even more compelling is the fact that 80% of Cadence's revenue is now recurring revenue, meaning its customers are making ongoing, regular payments to access this software. It's much easier -- and cheaper -- to retain a customer than win one in the first place. A new kind of networking solution Cisco Systems may be the biggest name in the networking business, but it's not necessarily the best investment opportunity within the industry. That honor arguably belongs to smaller Arista Networks (NYSE: ANET). At first blush, the two companies seem similar enough. As was noted, both are networking solutions providers, offering a range of switches and buffers. There is a nuanced but important difference between these two outfits, though. That is, most of Arista's tech is built around its Extensible Operating System that can be updated and/or rewritten as merited. Because its switches are always equipped to meet ever-changing functionality needs, they will remain useful for longer. This ultimately translates into lower lifetime equipment costs for campuses, telecommunications service providers, and the like. Analysts are looking for sales growth of more than 19% this year and next, although this pace of growth is apt to last far longer in light of the solution that Arista brings to the table. Think small for big growth and big profits Most investors have heard of Vertex Pharmaceuticals (NASDAQ: VRTX). Most people, however, would be hard-pressed to name a single drug it makes. But that's kind of the point. It's predominantly a specialty pharma company, focusing on relatively rare diseases and underserved markets. Vertex is really, really good at what it does. Last year's revenue of just over $11 billion was up 12% from 2023's sales, and the company is looking for sales of nearly $12 billion this year following two key approvals. If all goes as expected, 2025 is going to mark the pharma company's 11th straight year of double-digit revenue growth. Given its pipeline that includes two phase 3 clinical trials in addition to four phase 2 trials, however, it's certainly possible that firmly profitable Vertex can keep the streak alive for far longer than that. If it works, it works You've probably never heard of Coupang (NYSE: CPNG). But don't sweat it. It's relatively new as well as relatively small. And, although headquartered in the United States, it mostly serves the South Korean market. The company did $30 billion worth of business last year, up 24%. But what is it? Like so many other technology companies these days, it's a little bit of everything. Its core business is e-commerce and delivery of online orders, but its distinguishing detail is its exposure to the grocery and restaurant-prepared food delivery market. Yet it's also a major middleman for entertainment events -- digital as well as in-person -- an online payment platform, and a seller of luxury goods. The thing is, this disjointed assembly of ventures seems to work, perhaps because the company's management fully understands its core geographic market and its consumers. Electric vehicle mania is still alive and well ... in China U.S. consumers may have lost their lovin' feelin' for electric vehicles, just as the U.S. electric vehicle industry lost much of its political support (in the form of subsidies). But this isn't the case outside of the United States. The rest of the world still loves the idea of emissions-free electric vehicles, including most foreign governments. And it's particularly true in China, where EV maker Nio (NYSE: NIO) is located, and where it does the bulk of its growing business. It delivered nearly 222,000 electric cars in 2024, up 39% from the previous year's count. This growth pace has persisted into the first half of this year as well, boosted by sustained demand for electric vehicles in China and its neighbors. Indeed, the International Energy Administration says electric vehicles accounted for nearly half of China's automobile sales in 2024. There's plenty more where that came from, too. The IEA adds that by 2030, this proportion should reach 80% of the country's total vehicle sales. The data center industry can't grow without it Finally, add Applied Digital (NASDAQ: APLD) to your list of brilliant growth stocks to buy and hold for the long haul. It's an opportunity hiding in plain sight. The rapid growth of artificial intelligence data centers? Most investors are so focused on the technology being used inside them that they're not even thinking about who's building the buildings themselves. It's Applied Digital, for one, which is arguably the best and most (if not only) investment-worthy one. It's easier said than done. As you likely know, AI data centers are incredibly power-hungry, so much so that onsite nuclear power is being considered as a cost-effective source of the electricity they need. Applied Digital isn't just stacking up processors. It's figuring out how to provide the power that data centers need at the lowest cost possible. This might put things in perspective. Although this year's forecasted top-line growth of more than 34% is likely to cool to nearly nil next year, this company's revenue is expected to more than double in 2027, and then triple this year's sales in 2028. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor 's total average return is1,049% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ASML, Amazon, Arista Networks, Cadence Design Systems, Cisco Systems, Intel, Intuitive Surgical, Lam Research, Microsoft, Shopify, Taiwan Semiconductor Manufacturing, Vertex Pharmaceuticals, and Walmart. The Motley Fool recommends Alibaba Group and Coupang and recommends the following options: long January 2026 $395 calls on Microsoft, short August 2025 $24 calls on Intel, and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
2 hours ago
- Globe and Mail
This Stock Outperformed Nvidia and Palantir in the First Half. Is It Still a Buy?
Key Points CoreWeave stock surged by 300% in just a few months. The company is benefiting from high demand for computing power to support AI training and inferencing. 10 stocks we like better than CoreWeave › Over the past couple of years, Nvidia (NASDAQ: NVDA) and Palantir Technologies (NASDAQ: PLTR) have both shown their strengths in artificial intelligence (AI) -- and as a result, their earnings and stock performance have soared. Last year, Nvidia was the best-performing component in the Dow Jones Industrial Average (though it only was added to the venerable blue chip index in November), and Palantir posted the biggest gain in the S&P 500. Both of these players have continued to advance, and considering that we're in the early stages of the AI boom, more earnings growth and stock price gains could be on the way. But, in the first half of 2025, another company emerged as a potential AI powerhouse. In fact, this particular stock actually outperformed Nvidia and Palantir in the period, climbing by a mind-boggling 300%. Now you may be wondering whether this high flyer is still a buy. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » A company with close ties to Nvidia This top-performing AI stock actually is new to the market, completing its initial public offering in late March, so its triple-digit gains took place over a period of only three months. I'm referring to CoreWeave (NASDAQ: CRWV), a company that is closely linked to Nvidia. This is because CoreWeave generates most of its revenue by renting out access to its vast collection of Nvidia graphics processing units (GPUs). The company has more than 250,000 of them deployed across its cloud infrastructure platform, and it specializes in handling AI workloads, offering customers the configurations they need to accomplish their goals faster. CRWV data by YCharts. Nvidia owns a 7% stake in CoreWeave, and made it possible for the young company to be the first to launch its latest GPUs. In February, CoreWeave became the first hyperscaler to make Nvidia's new Blackwell architecture broadly available -- and it just did the same recently with the latest iteration, Blackwell Ultra. So, a bet on CoreWeave is a bet on demand for Nvidia's latest chips. Its first-quarter earnings report showed this demand is going strong, as its revenue climbed by more than 400% year over year, and Nvidia's own Q1 earnings report offered additional clues: For example, Nvidia said it saw a leap in demand for inferencing computing power in the quarter. This sort of trend is likely to benefit CoreWeave. GPUs to fuel inferencing Inferencing is the process an AI model goes through when attempting to answer complex questions -- and it takes significant parallel processing power of the type provided by GPUs and other AI accelerators. As more people and organizations apply AI to real-world problems, inferencing could drive a whole new era of growth for companies like Nvidia and CoreWeave. It's important to remember that the need for GPUs doesn't end once a model is trained. CoreWeave's fleet of cloud servers may have plenty of busy days ahead over the long term. All of this is great, but CoreWeave still carries some risk for shareholders -- and that's due to the enormous and ongoing investments in infrastructure required to serve demand for GPUs. The company will have to keep up its capital spending to increase the size and power of its fleet of GPU clusters, and considering that Nvidia aims to roll out new chip architectures annually, CoreWeave will have to make those investments frequently to keep its offerings top of the line. All of this makes it difficult to estimate when CoreWeave will reach profitability. In the first quarter, its technology and infrastructure expenses surged by more than 500% to about $500 million, and it's fair to say the company is early in its growth story. It's also important to note that CoreWeave is in an expansion phase that involves other investments too. Some of those up-front costs may result in savings down the road. Acquiring Core Scientific One example is the company's recently announced plan to buy Core Scientific -- once that deal closes, CoreWeave no longer will have to pay rent to the data center operator, resulting in the savings of $10 billion in future lease payments. Though this will be a positive, CoreWeave's stock fell after the announcement earlier this week due to investors' concerns about share dilution -- it's an all-stock deal with a value of $9 billion. Investors also know that any acquisition comes with some risks and costs, as the buyer will have to integrate its new operations into its existing business. So the question remains: After strongly outperforming two of the market's biggest AI companies year to date, is CoreWeave still a buy? The answer depends on your investment strategy. If you're a cautious or value investor, you'd be better off exploring other opportunities. But if you're an aggressive investor who buys and holds stocks for the long term, now would still be a good time to add a few CoreWeave shares to your portfolio -- demand for AI and CoreWeave's immediate access to Nvidia's latest GPUs could result in major gains over the long run. Should you invest $1,000 in CoreWeave right now? Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor 's total average return is1,049% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025
